
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About
Sight Sciences Inc (SGHT)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SGHT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $4.27
1 Year Target Price $4.27
2 | Strong Buy |
0 | Buy |
6 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -8.42% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 222.56M USD | Price to earnings Ratio - | 1Y Target Price 4.27 |
Price to earnings Ratio - | 1Y Target Price 4.27 | ||
Volume (30-day avg) 8 | Beta 2.44 | 52 Weeks Range 2.03 - 7.05 | Updated Date 08/15/2025 |
52 Weeks Range 2.03 - 7.05 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.96 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.26 | Actual -0.23 |
Profitability
Profit Margin -64.23% | Operating Margin (TTM) -59.63% |
Management Effectiveness
Return on Assets (TTM) -22.4% | Return on Equity (TTM) -57.1% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 161631275 | Price to Sales(TTM) 2.92 |
Enterprise Value 161631275 | Price to Sales(TTM) 2.92 | ||
Enterprise Value to Revenue 2.12 | Enterprise Value to EBITDA -4.25 | Shares Outstanding 52367400 | Shares Floating 28843941 |
Shares Outstanding 52367400 | Shares Floating 28843941 | ||
Percent Insiders 20.61 | Percent Institutions 52.73 |
Upturn AI SWOT
Sight Sciences Inc
Company Overview
History and Background
Sight Sciences Inc. was founded in 2011 and is focused on developing and commercializing innovative surgical and nonsurgical technologies intended to transform care and improve outcomes for patients with ophthalmic diseases. They have grown through product development and commercialization.
Core Business Areas
- Glaucoma: Developing and marketing devices to address glaucoma, including the OMNI Surgical System and VISCO 360 Viscosurgical System, aimed at reducing intraocular pressure.
- Dry Eye: Focused on technologies such as TearCare System, designed for the treatment of dry eye disease via localized heat therapy and meibomian gland expression.
Leadership and Structure
Paul Badawi serves as the Chief Executive Officer. The company has a board of directors and operates with functional teams across R&D, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- OMNI Surgical System: A microinvasive glaucoma surgery (MIGS) device used to reduce intraocular pressure in patients with glaucoma. Market share data is not explicitly public, but it's a competitive market with established players such as Glaukos (GKOS) and Ivantis. Competitors: Glaukos (GKOS), Ivantis, Alcon (ALC).
- TearCare System: A device used for the treatment of dry eye disease. It applies controlled heat to the meibomian glands to improve gland function. Competitors include Johnson & Johnson Vision (JJNJ), Lumenis, and Allergan (ABBV).
Market Dynamics
Industry Overview
The ophthalmic market is driven by an aging population and technological advancements in diagnostics and treatments. Glaucoma and dry eye represent significant areas of unmet need and market opportunity.
Positioning
Sight Sciences Inc. is positioned as an innovator in the ophthalmic surgical and nonsurgical space, focusing on novel approaches to treating glaucoma and dry eye. Their competitive advantage lies in their proprietary technology and targeted treatment solutions.
Total Addressable Market (TAM)
The TAM for glaucoma and dry eye treatments is estimated to be in the billions of dollars annually. Sight Sciences Inc. aims to capture a significant share of this market through expanding their product portfolio and market penetration.
Upturn SWOT Analysis
Strengths
- Innovative Product Portfolio
- Proprietary Technology
- Strong Focus on Ophthalmic Diseases
- Growing Revenue
Weaknesses
- Limited Market Share Compared to Established Competitors
- Dependence on Reimbursement Policies
- Relatively small company size in market with large players
- History of net losses
Opportunities
- Expanding Product Applications
- Entering New Geographic Markets
- Strategic Acquisitions or Partnerships
- Increasing Awareness of Dry Eye and Glaucoma
Threats
- Competition from Larger, More Established Companies
- Changes in Healthcare Regulations
- Product Liability Risks
- Economic Downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- ALC
- GKOS
- ABBV
Competitive Landscape
Sight Sciences Inc. faces competition from larger, more established companies with greater resources. Their advantage lies in their innovative technology, while their disadvantage is their relatively smaller size and limited market share.
Growth Trajectory and Initiatives
Historical Growth: Sight Sciences Inc. has demonstrated strong revenue growth in recent years, driven by increased adoption of their products.
Future Projections: Analysts project continued revenue growth for Sight Sciences Inc., driven by expanding market penetration and new product launches.
Recent Initiatives: Recent initiatives include expanding the sales force, launching new products, and pursuing strategic partnerships.
Summary
Sight Sciences Inc. is a growing company with innovative ophthalmic solutions, showing strong revenue growth but struggling with profitability. They operate in a competitive market and need to carefully manage expenses and secure reimbursement to achieve long-term success. Market penetration and continued innovation are key to competing with larger players. Maintaining sufficient cash to fund operations is essential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Industry Publications
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Market share data is approximate and based on publicly available information. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sight Sciences Inc
Exchange NASDAQ | Headquaters Menlo Park, CA, United States | ||
IPO Launch date 2021-07-15 | Co-Founder, President, CEO & Director Mr. Paul Badawi | ||
Sector Healthcare | Industry Medical Devices | Full time employees 216 | Website https://www.sightsciences.com |
Full time employees 216 | Website https://www.sightsciences.com |
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases. The company operates in two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform a comprehensive procedure indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, as well as for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and SION surgical instrument, a bladeless manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The company also provides TearCare system, a dry eye device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.